These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 34890875)
61. Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires. Petersen BM; Ulmer SA; Rhodes ER; Gutierrez-Gonzalez MF; Dekosky BJ; Sprenger KG; Whitehead TA Front Immunol; 2021; 12():728694. PubMed ID: 34646268 [TBL] [Abstract][Full Text] [Related]
62. Developability assessment for monoclonal antibody drug candidates: a case study. Garripelli VK; Wu Z; Gupta S Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499 [TBL] [Abstract][Full Text] [Related]
63. Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants. Kuramochi T; Gan SW; Ho AWS; Wang B; Kageji N; Nambu T; Iida S; Okuda-Miura M; Chia WS; Yeo CY; Chen D; Lee WH; Ngoh EZX; Mohd Salleh SN; Wang CI; Igawa T; Shimada H MAbs; 2022; 14(1):2040350. PubMed ID: 35293276 [TBL] [Abstract][Full Text] [Related]
64. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Parola C; Neumeier D; Reddy ST Immunology; 2018 Jan; 153(1):31-41. PubMed ID: 28898398 [TBL] [Abstract][Full Text] [Related]
65. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. Buck PM; Chaudhri A; Kumar S; Singh SK Mol Pharm; 2015 Jan; 12(1):127-39. PubMed ID: 25383990 [TBL] [Abstract][Full Text] [Related]
67. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Xu Y; Roach W; Sun T; Jain T; Prinz B; Yu TY; Torrey J; Thomas J; Bobrowicz P; Vásquez M; Wittrup KD; Krauland E Protein Eng Des Sel; 2013 Oct; 26(10):663-70. PubMed ID: 24046438 [TBL] [Abstract][Full Text] [Related]
68. Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties. Li L; Kumar S; Buck PM; Burns C; Lavoie J; Singh SK; Warne NW; Nichols P; Luksha N; Boardman D Pharm Res; 2014 Nov; 31(11):3161-78. PubMed ID: 24906598 [TBL] [Abstract][Full Text] [Related]
69. Broad epitope coverage of a human in vitro antibody library. Sivasubramanian A; Estep P; Lynaugh H; Yu Y; Miles A; Eckman J; Schutz K; Piffath C; Boland N; Niles RH; Durand S; Boland T; Vásquez M; Xu Y; Abdiche Y MAbs; 2017 Jan; 9(1):29-42. PubMed ID: 27748644 [TBL] [Abstract][Full Text] [Related]
70. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR MAbs; 2020; 12(1):1787121. PubMed ID: 32658605 [TBL] [Abstract][Full Text] [Related]
71. Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody. Deokar V; Sharma A; Mody R; Volety SM J Pharm Sci; 2020 Dec; 109(12):3579-3589. PubMed ID: 32946895 [TBL] [Abstract][Full Text] [Related]
72. AF4 and PEG Precipitation as Predictive Assays for Antibody Self-Association. Condado-Morales I; Sokolova V; Wahlund PO; Heding KE; Auclair S; Kingsbury JS; Arosio P; Lorenzen N Mol Pharm; 2023 Feb; 20(2):1323-1330. PubMed ID: 36668814 [TBL] [Abstract][Full Text] [Related]
73. Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform. Foltz IN; Gunasekaran K; King CT Immunol Rev; 2016 Mar; 270(1):51-64. PubMed ID: 26864104 [TBL] [Abstract][Full Text] [Related]